Ignite Creation Date:
2025-12-24 @ 5:56 PM
Ignite Modification Date:
2026-01-02 @ 1:56 PM
Study NCT ID:
NCT05806268
Status:
COMPLETED
Last Update Posted:
2023-04-10
First Post:
2023-03-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-07-30
Start Date Type:
ACTUAL
Primary Completion Date:
2022-03-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-03-28
Completion Date Type:
ACTUAL
First Submit Date:
2023-03-28
First Submit QC Date:
None
Study First Post Date:
2023-04-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-28
Last Update Post Date:
2023-04-10
Last Update Post Date Type:
ACTUAL